Renal Anemia – Landscape & Forecast – Disease Landscape & Forecast
Renal anemia is a common complication of chronic kidney disease (CKD). Although there are treatments for the disease, physicians, patients, and healthcare systems have concerns about their limitations. Delivery, safety issues, and tightening healthcare budgets have resulted in increased scrutiny of the effectiveness and tolerability of such therapies as intravenous (IV) iron and erythropoiesis-stimulating agents (ESAs). The renal anemia therapy market will expand over the 2021-2031 study period, fueled by increasing prevalence and demand for new drugs that can effectively, safely, and conveniently control the disease. The launches of several hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitors are expected during the study period. Although these new therapies offer advantages over current therapies, they will face major challenges, including reimbursement hurdles and an increasingly stringent regulatory environment.
QUESTIONS ANSWERED
- What are the opportunities for marketers of the emerging oral HIF-PH inhibitors to promote their noninvasive route of administration, particularly for patients not on dialysis?
- Will establishing cardiovascular (CV) safety be key for the market uptake of HIF-PH inhibitors, in view of the CV issues associated with current therapies?
- With the imminent availability of biosimilars in the United States, how will emerging therapies that offer only incremental improvements over existing therapies fare?
CONTENT HIGHLIGHTS
- Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
- Primary research: 20 country-specific interviews with thought-leading nephrologists. Supported by survey data collected for this and other Clarivate research.
- Epidemiology: Prevalence of renal anemia by country and diagnosed / drug-treated rates.
- Emerging therapies: Coverage of select emerging therapies from preclinical to preregistration stages.
- Market forecast features: 10-year, annualized, drug-level sales and patient share of key renal anemia therapies through 2031, segmented by brands / generics.
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
SOLUTION ENHANCEMENT
Disease Landscape & Forecast will feature continuous updates in 2023 to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Table of contents
- Renal Anemia - Landscape & Forecast - Disease Landscape & Forecast
- Key findings
- Renal anemia key findings - February 2023
- Key updates
- February 2023
- Q3 2022
- September 2022
- Q2 2022
- June 2022
- April 2022
- Market outlook
- Key findings
- Market share of drug classes for renal anemia, dialysis: 2021
- Market share of drug classes for renal anemia, non-dialysis: 2021
- Market share of drug classes for renal anemia, dialysis: 2031
- Market share of drug classes for renal anemia, non-dialysis: 2031
- Renal anemia SWOT analysis
- Market drivers and constraints
- What factors are driving the market for renal anemia?
- What factors are constraining the market for renal anemia?
- Key market events for renal anemia: 2021-2031
- Drug-class-specific trends
- Annual sales of hypoxia-inducible factor-prolyl hydroxylase inhibitors in renal anemia, dialysis, in the major markets: 2021-2031
- Annual sales of hypoxia-inducible factor-prolyl hydroxylase inhibitors in renal anemia, non-dialysis, in the major markets: 2021-2031
- Patient share of hypoxia-inducible factor-prolyl hydroxylase inhibitors in renal anemia, dialysis, in the major markets: 2021-2031
- Patient share of hypoxia-inducible factor-prolyl hydroxylase inhibitors in renal anemia, non-dialysis, in the major markets: 2021-2031
- Annual sales of erythropoietin-stimulating agents in renal anemia, dialysis, in the major markets: 2021-2031
- Annual sales of erythropoietin-stimulating agents in renal anemia, non-dialysis, in the major markets: 2021-2031
- Patient share of select erythropoietin-stimulating agents in renal anemia, dialysis, in the major markets: 2021-2031
- Patient share of select erythropoietin-stimulating agents in renal anemia, non-dialysis, in the major markets: 2021-2031
- Key findings
- Forecast
- Market forecast assumptions u2013 renal anemia nondialysis
- Market forecast assumptions u2013 renal anemia dialysis
- Market forecast dashboard - renal anemia nondialysis
- Market forecast dashboard - renal anemia dialysis
- Etiology and pathophysiology
- Disease overview
- Select diagnostic criteria for renal anemia
- Etiology
- Factors contributing to renal anemia
- Pathophysiology
- Pathophysiological mechanism in renal anemia
- Disease progression
- Classification of chronic kidney disease by severity
- Key pathways and drug targets
- Drug targets
- Epidemiology
- Key findings
- Epidemiology populations
- Disease definition
- Methods
- Sources used for prevalence of renal anemia
- Total prevalent cases of renal anemia (thousands): 2021-2031
- Disease definition
- Methods
- Sources used for prevalent cases of renal anemia by dialysis
- Total prevalent cases of renal anemia by dialysis status (thousands): 2021-2031
- Diagnosed prevalent cases of renal anemia in dialysis (thousands): 2021-2031
- Diagnosed prevalent cases of renal anemia in chronic kidney disease nondialysis (thousands): 2021-2031
- Drug-treated prevalent cases of renal anemia in dialysis (thousands): 2021-2031
- Drug-treated prevalent cases of renal anemia in chronic kidney disease nondialysis (thousands): 2021-2031
- Key findings
- Current treatment
- Key findings
- Treatment goals
- Key endpoints used in clinical trials for renal anemia
- Hemoglobin targets: select renal anemia guidelines
- Key current therapies
- Overview
- Mechanism of action of key current drug classes used for renal anemia
- Current treatments used for renal anemia
- Market events impacting the use of key current therapies in renal anemia
- Advantages and disadvantages of epoetin alfa
- Expert insight: epoetin alfa
- Advantages and disadvantages of epoetin beta
- Expert insight: epoetin beta
- Advantages and disadvantages of epoetin theta
- Advantages and disadvantages of darbepoetin alfa
- Expert insight: darbepoetin alfa
- Advantages and disadvantages of methoxy polyethylene glycol-epoetin beta
- Expert insight: methoxy polyethylene glycol-epoetin beta
- Advantages and disadvantages of ferric citrate
- Expert insight: ferric citrate
- Advantages and disadvantages of iron supplements
- Expert insight: iron supplements
- Advantages and disadvantages of roxadustat
- Advantages and disadvantages of vadadustat
- Advantages and disadvantages of enarodustat
- Advantages and disadvantages of molidustat
- Expert insight: hypoxia-inducible factor-prolyl hydroxylase inhibitors
- Medical practice
- Overview
- Factors influencing drug selection in renal anemia
- Treatment decision tree for renal anemia: United States
- Treatment decision tree for renal anemia: Europe
- Treatment decision tree for renal anemia: Japan
- Key findings
- Unmet need overview
- Current and future attainment of unmet needs in renal anemia
- Top unmet needs in renal anemia: current and future attainment
- Expert insight: unmet need in renal anemia
- Emerging therapies
- Key findings
- Key emerging therapies
- Key therapies in development for renal anemia
- Estimated launch dates of key emerging therapies for the treatment of renal anemia
- Daprodustat profile
- Analysis of the clinical development program for daprodustat
- Expert insight: daprodustat
- Expectations for launch and sales opportunity of daprodustat in renal anemia
- Early-phase pipeline analysis
- Select compounds in early-phase development for renal anemia
- Key findings
- Access & reimbursement overview
- Region-specific reimbursement practices
- Key market access considerations in renal anemia: United States
- General reimbursement environment: United States
- Key market access considerations in renal anemia: EU5
- General reimbursement environment: EU5
- Key market access considerations in renal anemia: Japan
- General reimbursement environment: Japan
- Region-specific reimbursement practices
- Appendix
- Abbreviation
- Renal anemia bibliography
- Key findings
Tej Pal, M.Pharm., is a senior healthcare research & data analyst on the Cardiovascular, Metabolic, Renal, and Hematologic Diseases team at Clarivate. He has authored several reports focusing on metabolic and renal indications. Previously, he was an analyst at IQVIA and at Smart Analyst Inc., where he worked closely with top pharmaceutical companies on commercial and technical ad-hoc requests. During his tenure there, he delivered competitive landscape and market insight projects on various oncology indications. He holds a master’s degree in pharmacy with a specialization in pharmaceutical chemistry from the Delhi Institute of Pharmaceutical Sciences and Research in New Delhi, India.